醋酸戈舍瑞林缓释植入剂联合米非司酮治疗子宫肌瘤的临床效果及不良反应分析

Analysis of clinical efficacy and adverse reactions of goserrelin acetate sustained-release depot combined with mifepristone in the treatment of uterine fibroids

目的分析子宫肌瘤采取米非司酮与醋酸戈舍瑞林缓释植入剂联合治疗的效果、不良反应。方法80例子宫肌瘤患者,依据随机数字表法分为对照组与研究组,每组40例。对照组利用醋酸戈舍瑞林缓释植入剂实施治疗,研究组利用醋酸戈舍瑞林缓释植入剂和米非司酮联合治疗。对比两组患者的临床疗效、血液流变学指标(血浆比粘度、红细胞聚集指数、纤维蛋白原)、性激素指标[黄体生成素(LH)、雌二醇(E2)、卵泡刺激素(FSH)]、子宫肌瘤体积及不良反应发生情况。结果研究组患者治疗总有效率95.00%比对照组的80.00%高,差异有统计学意义(P<0.05)。治疗后,研究组患者的血浆比粘度(0.89±0.20)、纤维蛋白原(2.13±0.34)g/L、红细胞聚集指数(48.78±6.99)%比对照组的(1.65±0.30)、(3.97±0.64)g/L、(64.12±7.34)%低,差异有统计学意义(P<0.05)。治疗后,研究组患者的LH(10.64±2.96)U/L、E2(138.78±18.32)pmol/L、FSH(11.97±2.86)U/L比对照组的(13.52±2.81)U/L、(200.23±36.56)pmol/L、(17.15±4.33)U/L低,差异有统计学意义(P<0.05)。治疗后,研究组患者子宫肌瘤体积(5.24±1.01)cm3比对照组的(11.63±1.78)cm3小,差异有统计学意义(P<0.05)。治疗后,研究组不良反应发生率为15.00%,对照组不良反应发生率为7.50%,两组对比差异无统计学意义(P>0.05)。结论子宫肌瘤采取米非司酮与醋酸戈舍瑞林缓释植入剂联合治疗效果较好,能对患者的血液流变学水平进行改善,对其性激素指标进行调节,使患者子宫肌瘤的体积有效缩小,促进其早日康复,具有一定的临床应用与研究价值。

Objective To analyze the effect and adverse reactions of goserrelin acetate sustained-release depot combined with mifepristone in the treatment of uterine fibroids.Methods 80 patients with uterine fibroids were divided into a control group and a study group according to random number table method,with 40 cases in each group.The control group was treated with goserrelin acetate sustained-release depot,and the study group was treated with goserrelin acetate sustained-release depot and mifepristone.Comparison was made on clinical efficacy,hemorheological indexes(plasma viscosity,erythrocyte aggregation index,fibrinogen),sex hormone indexes[luteinizing hormone(LH),estradiol(E2),follicle stimulating hormone(FSH)],uterine fibroid volume,and the occurrence of adverse reactions between the two groups.Results The total effective rate of 95.00%in the study group was higher than 80.00%in the control group,and the difference was statistically significant(P<0.05).After treatment,the plasma specific viscosity in the study group was(0.89±0.20),the fibrinogen was(2.13±0.34)g/L and the erythrocyte aggregation index was(48.78±6.99)%,which were lower than(1.65±0.30),(3.97±0.64)g/L and(64.12±7.34)%in the control group.The difference was statistically significant(P<0.05).After treatment,the study group had LH of(10.64±2.96)U/L,E2 of(138.78±18.32)pmol/L,FSH of(11.97±2.86)U/L,which were lower than(13.52±2.81)U/L,(200.23±36.56)pmol/L,(17.15±4.33)U/L in the control group,and the difference was statistically significant(P<0.05).After treatment,the uterine fibroid volume of 33(5.24±1.01)cm in the study group was smaller than(11.63±1.78)cm in the control group,and the difference was statistically significant(P<0.05).After treatment,the incidence of adverse reactions was 15.00%in the study group and 7.50%in the control group,and there was no statistical significance between the two groups(P>0.05).Conclusion The combination of mifepristone and goserrelin acetate sustained-release depot in the treatment of uterine fibroids has a good effect,which can improve the hemorheology level of patients,adjust their sex hormone indexes,effectively shrink the uterine fibroid volume of patients,and promote their early recovery.It has certain clinical application and research value.